Quick Answer
Summit Therapeutics Inc. reported Stockholders Equity of $658.86 million for fiscal year 2025.
Summit Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $658.86M | +69.5% |
| 2024 | $388.75M | +400.4% |
| 2023 | $77.69M | -38.7% |
| 2022 | $126.65M | +52.1% |
| 2021 | $83.28M | +4.8% |
| 2020 | $79.45M | +0.7% |
| 2019 | $78.86M | +36.9% |
| 2019 | $57.59M | +1704.6% |
| 2018 | -$3.59M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $192.26M | -56.1% | -25.9% |
| June 30, 2025 | $259.44M | +33.0% | -24.7% |
| March 31, 2025 | $344.33M | +678.9% | -11.4% |
| December 31, 2024 | $388.75M | +400.4% | -11.2% |
| September 30, 2024 | $437.92M | +340.7% | +124.5% |
| June 30, 2024 | $195.07M | +63.1% | +341.2% |
| March 31, 2024 | $44.21M | -66.9% | -43.1% |
| December 31, 2023 | $77.69M | -38.7% | -21.8% |
- Summit Therapeutics Inc. showed an increase of +69.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Summit Therapeutics Inc.’s stockholders equity has grown by 18457.8% (from -$3.59 million to $658.86 million).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: